eligibility_summary
Dose escalation: R/R metastatic RCC, EBV+ NPC, or advanced NHL (DLBCL/FL/MCL), prior therapy: RCC TKI+PD-(L)1, NPC platinum, NHL >=2 lines, measurable disease. Exclude prior CD70 or topo-1 ADC, allo-HSCT, active CNS mets. Expansion: R/R DLBCL, >=2 lines incl anti-CD20, measurable, ECOG 0-2, CD70 biopsy. Exclude CNS disease, recent therapy/SCT or investigational drug, high-dose steroids/immunosuppression, autoimmune, major cardiac, unresolved tox, GVHD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: GEN1160 (PRO1160), an intravenous CD70-targeted antibody–drug conjugate (ADC). Mechanism: The anti‑CD70 antibody binds CD70 on tumor cells, is internalized, and releases a cytotoxic payload (topoisomerase I–inhibitor class per trial exclusions), causing DNA damage and tumor cell death. Type: biologic immunotherapy/ADC. Targets: CD70‑expressing malignant cells in renal cell carcinoma (RCC), Epstein–Barr virus–associated nasopharyngeal carcinoma (NPC), and B‑cell non‑Hodgkin lymphomas—especially diffuse large B‑cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. Pathway/cell focus: CD70 on tumor/activated lymphocytes (CD70/CD27 axis).